Results 41 to 50 of about 490,354 (259)

SARS‐CoV‐2 infection with bilateral intralabyrinthine hemorrhage

open access: yesClinical Case Reports, 2022
A 47‐year‐old woman presented with the complaint of sudden hearing loss associated with vertigo. Serological testing was positive for IgM and negative for IgG COVID‐19 antibodies, with no other associated factors.
Vagner Antonio Rodrigues daSilva   +6 more
doaj   +1 more source

Taking on SARS-CoV-2

open access: yeseLife, 2022
A new study sheds light on how SARS-CoV-2 influences the way natural killer cells can recognize and kill infected cells.
Paola Kučan Brlić, Ilija Brizić
openaire   +5 more sources

SARS‐CoV‐2 Omicron variant: Characteristics and prevention

open access: yesMedComm, 2021
Coronavirus disease 2019 (COVID‐19) has brought about a great threat to global public health. Recently, a new severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) variant B.1.1.529 has been reported in South Africa and induced a rapid increase in
Xuemei He   +4 more
doaj   +1 more source

Biophysical approaches for studying viral entry

open access: yesFEBS Letters, EarlyView.
Viruses infect all living organisms and have been responsible for major epidemics and pandemics. Their ongoing evolutionary battle with host defenses creates a constant need for improved tools to study viral behavior. Advancing methods to probe viral attachment, fusion, and genome release deepen our understanding of how infections begin and support the
Inbar Yosibash, Raya Sorkin
wiley   +1 more source

Erythema Multiforme Major following SARS‐CoV‐2 vaccine

open access: yesClinical Case Reports, 2021
Erythema multiforme major, an immune‐mediated skin reaction to infections or medications with oral involvement, should be taken into account as a potential side effect of several vaccines, including SARS‐CoV‐2.
Alberto Maria Saibene   +7 more
doaj   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

open access: yesFEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang   +2 more
wiley   +1 more source

SARS CoV- 2 vaccination induces antibodies against cardiolipin

open access: yesBMC Research Notes, 2022
Objective Cases of thrombosis have been reported after administration of SARS-CoV-2 vaccines, with controversial results relating to Oxford-AstraZeneca’s ChAdOx1-S.
George Krashias   +5 more
doaj   +1 more source

Genomic Sequencing and Phylogenomics of Cowpox Virus

open access: yesViruses, 2022
Cowpox virus (CPXV; genus Orthopoxvirus; family Poxviridae) is the causative agent of cowpox, a self-limiting zoonotic infection. CPXV is endemic in Eurasia, and human CPXV infections are associated with exposure to infected animals. In the Fennoscandian
Diana Diaz-Cánova   +5 more
doaj   +1 more source

Going viral − Virus‐targeting nanobodies for research, diagnostics and therapy

open access: yesFEBS Letters, EarlyView.
The increasing prevalence of viral diseases represents a major threat for global human health. Nanobodies, small binding fragments derived from camelid heavy‐chain antibodies, offer versatile tools for viral research, diagnostics, and antiviral therapy.
Domenic Ebert, Ulrich Rothbauer
wiley   +1 more source

From energy provision to protein synthesis: Tunnelling nanotubes as mediators of intercellular metabolic cooperation in cancer

open access: yesFEBS Open Bio, EarlyView.
The cytoskeleton‐mediated transport of mitochondria via tunnelling nanotubes restores respiration, increases ATP production, rescues cells from apoptosis, activates the AKT/mTOR signalling pathway, promotes cell migration and invasiveness, contributes to cancer progression and treatment resistance.
Stanislava Martínková, Jan Trnka
wiley   +1 more source

Home - About - Disclaimer - Privacy